Correction: Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancer

Correction: Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancer

Saved in:

Bibliographic Details
Main Authors:	Vera Höllriegl, Nina Petoussi-Henss, Kerstin Hürkamp, Juan Camilo Ocampo Ramos, Wei Bo Li
Format:	Article
Language:	English
Published:	SpringerOpen 2025-01-01
Series:	EJNMMI Physics
Online Access:	https://doi.org/10.1186/s40658-024-00708-1
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancer
by: Vera Höllriegl, et al.
Published: (2021-06-01)

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)

Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain
by: Eva Tirado Mercier, et al.
Published: (2018-01-01)

New Horizons In The Treatment Of Metastatic Castrate Resistant Prostate Cancer
by: Zein El Amir
Published: (2023-06-01)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01)

Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors
by: Zixi Wu, et al.
Published: (2025-12-01)

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
by: Joelle El-Amm, et al.
Published: (2013-01-01)

Clinical observations of patients with metastatic castration-resistant prostate cancer living in the Tambov region
by: P. G. Berezin, et al.
Published: (2023-09-01)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
by: Filippo Francini, et al.
Published: (2011-01-01)

Oral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources
by: Diana del Cisne Pineda, et al.
Published: (2025-01-01)

An MRI radiomics model for predicting a prostate-specific antigen response following abiraterone treatment in patients with metastatic castration-resistant prostate cancer
by: Yi Wu, et al.
Published: (2025-01-01)

Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Seiichi Kato, et al.
Published: (2021-01-01)

A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer
by: Aseem Samar, et al.
Published: (2020-01-01)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
by: Edgar Linden-Castro, et al.
Published: (2014-01-01)

New Therapeutics to Treat Castrate-Resistant Prostate Cancer
by: Ömer Acar, et al.
Published: (2013-01-01)

PARP inhibitor‐based treatment in metastatic, castration‐resistant prostate cancer (mCRPC): A systematic review and meta‐analysis
by: Michela Roberto, et al.
Published: (2025-01-01)

Evaluation of Tumor Viability for Primary and Bone Metastases in Metastatic Castration-Resistant Prostate Cancer Using Whole-Body Magnetic Resonance Imaging
by: Hiromichi Iwamura, et al.
Published: (2018-01-01)

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
by: Ulka Vaishampayan, et al.
Published: (2015-01-01)

Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer
by: Takahiro Inoue, et al.
Published: (2011-01-01)

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer
by: Jennifer H. Gunter, et al.
Published: (2012-01-01)

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01)

Real-world treatment patterns and survival outcomes in men with metastatic castration-resistant prostate cancer in Finland: a national, population-based cohort study
by: Antti Rannikko, et al.
Published: (2025-01-01)

Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects
by: Zahid Rafiq, et al.
Published: (2025-01-01)

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
by: Keith L. Davis, et al.
Published: (2015-01-01)

Generation of Whole-Genome Sequencing Data for Comparing Primary and Castration-Resistant Prostate Cancer
by: Jong-Lyul Park, et al.
Published: (2018-09-01)

Identification of mitochondrial carrier homolog 2 as an important therapeutic target of castration-resistant prostate cancer
by: Yankui Liu, et al.
Published: (2025-02-01)

Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis
by: Renliang Yi, et al.
Published: (2016-01-01)

Metastatic Breast Carcinoma to the Prostate Gland
by: Meghan E. Kapp, et al.
Published: (2016-01-01)

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis
by: Mike Fang, et al.
Published: (2017-01-01)

Stauffer’s Syndrome in Patient with Metastatic Prostate Cancer
by: Andris Romašovs, et al.
Published: (2019-01-01)

Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States
by: Catherine W. Saltus, et al.
Published: (2019-01-01)

The Current Role of Androgen Deprivation in Patients Undergoing Dose-Escalated External Beam Radiation Therapy for Clinically Localized Prostate Cancer
by: Michael J. Smith, et al.
Published: (2012-01-01)

Metastatic gastric adenocarcinoma in prostate: A case report
by: Naru Shimizu, et al.
Published: (2025-03-01)

New Primary Malignancy Masquerading as Metastatic Prostate Adenocarcinoma
by: Ellen A. Szwed, et al.
Published: (2015-01-01)

Activating Mutation (V617F) in the Tyrosine Kinase JAK2 is Absent in Locally-Confined or Castration-Resistant Prostate Cancer
by: Lei Gu, et al.
Published: (2010-01-01)

Pulmonary Tumor Thrombotic Microangiopathy from Metastatic Prostate Carcinoma
by: Dhruv Nayyar, et al.
Published: (2015-01-01)

An Unusual Case of Acute Appendicitis due to Metastatic Prostatic Adenocarcinoma
by: Numbereye Numbere, et al.
Published: (2020-01-01)

The absolute number of circulating Treg cells is reduced in difficult-to-treat RA patients and is ameliorated by low-dose IL-2
by: Huanhuan Yan, et al.
Published: (2025-02-01)

Effect of Age at Castration on Beef Calf Performance
by: Amie Imler, et al.
Published: (2013-03-01)

Does the Method of Castration Affect Calf Performance?
by: Trey Warnock, et al.
Published: (2014-02-01)